Immuron Limited (NASDAQ: IMRN) shares leaped 22.29% to 8.56 following no new advances have been announced by Biotech. But the benefit from Immuron undoubtedly represented the continuing confidence of some investors.
Usually, investors do not put much emphasis on major profits or losses, for that matter, on no information.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On a traditionally low-volume trading day, such movements are mostly just noise. What truly matters, regardless of transient price fluctuations, are the growth opportunities of the firm.
The last official update by the Australian biopharma corporation focusing on the production and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases was on November 24, 2020, that it had earned a cash rebate of AUD $358,280 for qualifying research and development under the Australian Government’s Research and Development Income Tax Concession reward scheme.
The directors of Immuron Limited have approved this publication.
